Are you a life science startup with fixed capital that needs to collect mission critical microscopy data? Or perhaps you are a larger organization with a need for instrumentation and expertise, but the timing isn’t right for a big purchase? Join in and learn more about the options.
Why should you join?
- Advanced imaging technologies
- Learn about 3D tissue and disease modes
- De-risking clinical stage programmes
- Highly relevant for startups and SME in biotech
- Leverage advanced image analysis as fee-for-service
Date: Monday 12 June 2023
Time: 9.00 - 9:45 CET
You'll have a chance to meet these people and hear short speeches from them.
Welcome, housekeeping & short intros
VitroScan – Better Informed Treatment DecisionsWillemijn Vader, CEO of VitroScan
Mimetas - High throughput assays for 3D tissue and disease modelsThomas Olivier, Bio-Informatics Engineer at Mimetas.
Wrapping up and goodbye
Sign up to joinPlease fill out the form to participate in the event.
COMPANIESIntroduce participating companies with a short text or delete this sentence.
VitroScan is a Dutch biotech company founded in 2016 and based at the Leiden Bio Science Park. VitroScan develops fast and accurate predictive testing for multiple cancers and treatments to support better informed treatment decisions for cancer patients. After a successful seed stage with Proof of Concept, the company develops certification, and clinical validation of its proprietary tumour testing platform. The services are offered to drug developers to de-risk clinical stage testing and clinicians for treatment decision support in oncology. The team consists of experienced and successful entrepreneurs, with extensive networks in fields of clinical oncology, pharma, (bio) information technology.
At MIMETAS we produce and leverage our organ-on-a-chip platform, the OrganoPlate®. By working with top pharmaceutical and biotech companies, we develop and establish physiologically relevant 3D tissue and disease models to develop novel therapies against unsolved diseases. By running high throughput, robust assays on these models, it enables the discovery of novel biological insights on the behaviour of cells as a result of compound treatments. We look forward to showcasing some of the imaging and assays we do and hope to inspire you to embrace humanized 3D tissue and disease models for your own research.